この記事を読む

ロルラチニブとALKバリアント3

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Typ…

この記事を読む

免疫療法後は何をしても変わらない?

Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens…

この記事を読む

オシメルチニブとアファチニブ交替療法、耐性機序が興味深い

Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single…

この記事を読む

肺炎のような粘液性肺腺癌の元は孤発型なのか?

Stepwise progression of invasive mucinous adenocarcinoma based on radiological and biological characteristics. Goto E et…

この記事を読む

T細胞エンゲ―ジャーは小細胞肺癌治療の新たな選択肢となるか?

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label…

この記事を読む

腫瘍治療電場療法、新たな希望か眉唾か

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-sm…

この記事を読む

トラスツズマブ・デルクステカンは減量でもなお肺臓炎の発症率が高い

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Rand…

この記事を読む

MET Exon14に患者背景に特徴はあるか

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. M…

この記事を読む

抗生物質と免疫チェックポイント阻害薬、まだまだ危うい

Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Canc…

この記事を読む

術後のctDNAの長期モニタリング、実用性はなかなか難しい?

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to ⅢA EGFR-Muta…